Add BrightSurf on Google Email

Cholesterol-craving cancers need lipid enzymes to use metabolites for growth

Researchers discover that kinases play a crucial role in moving cholesterol to activate a growth pathway in aggressive cancers. Without these enzymes, cancer cells are blocked from fueling tumor growth. The study highlights the importance of targeting lipid enzymes as a potential treatment strategy for cancers with TP53 mutations.

SourceSanford Burnham Prebys·JournalScience Advances·TypeExperimental study·DateMay 22, 2026

Short-circuiting pancreatic cancer

Researchers have discovered a complex regulatory circuit involving SRSF1, AURKA, and MYC that promotes aggressive pancreatic cancer progression. The circuit, which involves alternative splicing, can be targeted with an antisense oligonucleotide to reduce tumor cells' viability and trigger apoptosis.

SourceCold Spring Harbor Laboratory·JournalMolecular Cell·DateJan 8, 2026

Herpesvirus protein mimics host enzyme to balance infection and latency

Researchers discovered that herpesvirus protein kinases mimic human cyclin-dependent kinases, regulating viral infection and latency. Phosphorylation of the viral enzyme contributes to its survival and persistence, while phosphorylation downregulates its activity, allowing for balance between host survival and viral persistence.

SourceThe Institute of Medical Science, The University of Tokyo·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateApr 30, 2025

Study reveals hope for immunotherapy as prostate cancer treatment

Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...

SourceUniversity of Arizona Health Sciences·JournalCancer Immunology Research·TypeExperimental study·DateMar 4, 2025

New insights into the immune response of plants

A team of researchers has identified a calcium-activated bi-kinase module as the central molecular switch driving plant immune response. This discovery sheds light on how plants transmit immune signals from cell to cell without disrupting other signalling chains, using reactive oxygen species and calcium signals.

SourceUniversity of Münster·JournalScience Advances·TypeExperimental study·DateJan 27, 2025

Generative AI against diseases: Insilico Medicine announced Pharma.AI-powered HPK1 inhibitor series in peer-reviewed publication trilogy, as potential immunotherapy options

The study uses generative AI to identify and optimize potent and selective HPK1 inhibitors for immunotherapy. The results show a relatively balanced candidate compound with adequate in vitro ADME, in vivo PK properties, good oral bioavailability, and robust in vivo efficacy in various cancer models.

Controlling cancer cells’ gluttony for glutamine

Researchers at Sanford Burnham Prebys found that pancreatic cancer cells rely on a specific nutrient, glutamine, to fuel their unchecked growth. The study identified two enzymes, aPKC zeta and iota, that play a regulatory role in the process of macropinocytosis, allowing cancer cells to scavenge alternative resources.

SourceSanford Burnham Prebys·JournalNature Communications·TypeExperimental study·DateDec 5, 2024

Mount Sinai researchers introduce web portal empowering drug discovery and systems-level analysis of critical kinase-substrate interactions

KiNet is an interactive web portal that enables researchers to visualize and study kinase-substrate interactions in systemwide contexts. This facilitates the understanding of kinase functions and their implications in diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·Journalnpj Systems Biology and Applications·DateOct 3, 2024

Method improves detection of potential therapeutic tumor targets in human biopsies

A new method has been developed to detect potential therapeutic tumor targets in human biopsies, which could lead to more effective personalized medicine. The kinase inhibitor pulldown assay (KiP) enriches and quantifies small amounts of kinases present in biopsy samples, paving the way for future clinical applications.

SourceBaylor College of Medicine·JournalClinical Proteomics·TypeExperimental study·DateJan 16, 2024

Kinase-targeted therapy in subsets of colorectal cancer

Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.

SourceImpact Journals LLC·JournalOncoscience·TypeCommentary/editorial·DateSep 22, 2023

Dissecting the circadian clock in real time

Researchers at UC San Diego and UC Merced developed a high-throughput method to study the circadian clock in real time, shedding light on its internal functions. The study found that kinases play a crucial role in relaying the circadian rhythm from the core oscillator to gene expression.

SourceUniversity of California - San Diego·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 29, 2023

NIH researchers discover new autoinflammatory disease, suggest target for potential treatments

Scientists have identified an autoinflammatory disease called Lyn kinase-associated vasculopathy and liver fibrosis (LAVLI) linked to mutations in the LYN gene. The research suggests that Lyn kinase may be a potential therapeutic target for drugs treating non-syndromic small vessel vasculitis and inflammation-induced liver fibrosis.

Oncotarget | Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells

A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.

SourceImpact Journals LLC·JournalOncotarget·TypeLiterature review·DateMar 13, 2023

Immune cells have a backup mechanism

Researchers at University of Bonn discover a backup mechanism in immune cells that ensures efficient antiviral responses despite TBK1 enzyme mutations or complete loss. This mechanism relies on the stability of IKKepsilon protein, which compensates for TBK1 deficiency.

SourceUniversity of Bonn·JournalFrontiers in Immunology·TypeExperimental study·DateMar 10, 2023

Pathogenic sensor’s surprising capabilities revealed

Researchers developed a new way to study the sensory system used by pathogenic bacteria to infect humans. They screened thousands of peptides against a bacterial sensor and discovered 13 new human antimicrobial peptides (AMPs) that activate the sensor. The findings suggest an arms race between humans and bacteria, with each evolving ne...

SourceRice University·JournalNature Chemical Biology·TypeExperimental study·DateDec 12, 2022

Protein kinase CK2 has key role in killer T cells during infection by Listeria monocytogenes

The study found that protein kinase CK2 plays a key role in regulating CD8+ T cell activation, metabolic reprogramming and differentiation during infection by the intracellular pathogen Listeria monocytogenes. In mouse models, deletion of the CK2α catalytic subunit impaired CD8+ T cell function.

SourceUniversity of Alabama at Birmingham·JournalThe Journal of Immunology·TypeExperimental study·DateNov 1, 2022

Experimental drug to treat liver cancer shows evidence of activity with manageable side effects

A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 27, 2022

Cancer drug could potentially be used against malaria

Researchers found that sapanisertib can kill the malaria parasite at several stages during its life cycle, including in the liver and red blood cells. The study's findings offer new hope against a disease that kills over half a million people annually.

SourcePenn State·JournalScience Translational Medicine·TypeExperimental study·DateOct 26, 2022

CNIC scientists uncover opposing roles of p38 proteins in cardiac hypertrophy

A study by CNIC scientists has identified a key role for the MKK3/6–p38γ/δ signaling pathway in cardiac hypertrophy. Inhibition of p38α promotes an unexpected activation of the other branch of the pathway, consisting of the proteins MKK3, p38γ, and p38δ. This activation induces another key pathway in cardiac hypertrophy, the mTOR pathway.